| 4.29 -0.03 (-0.69%) | 06-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.38 | 1-year : | 5.74 |
| Resists | First : | 4.6 | Second : | 4.92 |
| Pivot price | 4.47 |
|||
| Supports | First : | 4.09 | Second : | 3.41 |
| MAs | MA(5) : | 4.49 |
MA(20) : | 4.51 |
| MA(100) : | 5.07 |
MA(250) : | 5.94 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 33.3 |
D(3) : | 48.4 |
| RSI | RSI(14): 39.2 |
|||
| 52-week | High : | 8.5 | Low : | 4.09 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SIGA ] has closed above bottom band by 26.7%. Bollinger Bands are 16.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.35 - 4.38 | 4.38 - 4.4 |
| Low: | 4.16 - 4.2 | 4.2 - 4.23 |
| Close: | 4.23 - 4.29 | 4.29 - 4.33 |
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
Fri, 22 May 2026
Discovering SIGA Technologies And 2 Other Compelling Penny Stocks - Yahoo Finance
Thu, 14 May 2026
Some Investors May Be Willing To Look Past SIGA Technologies' (NASDAQ:SIGA) Soft Earnings - Yahoo Finance
Thu, 14 May 2026
We Think You Can Look Beyond SIGA Technologies' (NASDAQ:SIGA) Lackluster Earnings - simplywall.st
Thu, 07 May 2026
SIGA Technologies (NASDAQ: SIGA) Q1 loss, dividend and mpox label change - Stock Titan
Thu, 07 May 2026
Earnings call transcript: SIGA Technologies reports Q1 2026 loss, anticipates Q2 revenue boost - Investing.com
Thu, 30 Apr 2026
SIGA CEO, CFO to discuss Q1 results and business update May 7 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 72 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 42.6 (%) |
| Held by Institutions | 49.9 (%) |
| Shares Short | 3,310 (K) |
| Shares Short P.Month | 3,240 (K) |
| EPS | 0.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.77 |
| Profit Margin | 21.5 % |
| Operating Margin | -85.3 % |
| Return on Assets (ttm) | 5.5 % |
| Return on Equity (ttm) | 11 % |
| Qtrly Rev. Growth | -11.4 % |
| Gross Profit (p.s.) | 0.56 |
| Sales Per Share | 1.3 |
| EBITDA (p.s.) | 0.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 28 (M) |
| Levered Free Cash Flow | 59 (M) |
| PE Ratio | 15.32 |
| PEG Ratio | 3.3 |
| Price to Book value | 1.54 |
| Price to Sales | 3.28 |
| Price to Cash Flow | 11.08 |
| Dividend | 0.6 |
| Forward Dividend | 0 |
| Dividend Yield | 13.9% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|